ES2188759T3 - Derivados de la dolastatina, su preparacion y su uso. - Google Patents

Derivados de la dolastatina, su preparacion y su uso.

Info

Publication number
ES2188759T3
ES2188759T3 ES96918661T ES96918661T ES2188759T3 ES 2188759 T3 ES2188759 T3 ES 2188759T3 ES 96918661 T ES96918661 T ES 96918661T ES 96918661 T ES96918661 T ES 96918661T ES 2188759 T3 ES2188759 T3 ES 2188759T3
Authority
ES
Spain
Prior art keywords
preparation
derivatives
dolastatine
new
antineoplasic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96918661T
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia A Romerdahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of ES2188759T3 publication Critical patent/ES2188759T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE DESCRIBEN NUEVOS DERIVADOS DE DOLASTATINA DE FORMULA (I): R 1 R 2 N - CHX - CO - A - B - D - E - (F) T K, EN DONDE R 1 , R 2 , A, B, D, E, F, K, X Y T TIENEN LOS SIGNIFICADOS QUE SE INDICAN EN LA DESCRIPCION, Y LA PREPARACION DE LOS MISMOS. LAS NUEVAS SUSTANCIAS TIENEN EFECTO ANTINEOPLASICO.
ES96918661T 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y su uso. Expired - Lifetime ES2188759T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides

Publications (1)

Publication Number Publication Date
ES2188759T3 true ES2188759T3 (es) 2003-07-01

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96918661T Expired - Lifetime ES2188759T3 (es) 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y su uso.
ES96918660T Expired - Lifetime ES2186783T3 (es) 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96918660T Expired - Lifetime ES2186783T3 (es) 1995-06-07 1996-06-03 Derivados de la dolastatina, su preparacion y uso.

Country Status (33)

Country Link
US (1) US5831002A (es)
EP (2) EP0871656B1 (es)
JP (2) JP4221062B2 (es)
KR (2) KR100437985B1 (es)
CN (2) CN1182154C (es)
AR (2) AR003136A1 (es)
AT (2) ATE224910T1 (es)
AU (2) AU725164B2 (es)
BG (2) BG102125A (es)
BR (2) BR9609423A (es)
CA (2) CA2219819C (es)
CO (2) CO4700527A1 (es)
CZ (2) CZ293682B6 (es)
DE (2) DE69623472T2 (es)
DK (2) DK0871656T3 (es)
ES (2) ES2188759T3 (es)
HR (2) HRP960257A2 (es)
HU (2) HU228071B1 (es)
IL (2) IL122215A (es)
MX (2) MX9709146A (es)
MY (2) MY119042A (es)
NO (2) NO318384B1 (es)
NZ (2) NZ310443A (es)
PL (2) PL185762B1 (es)
PT (2) PT832104E (es)
RO (2) RO118953B1 (es)
SI (2) SI0871656T1 (es)
SK (1) SK282466B6 (es)
TR (2) TR199701545T1 (es)
TW (2) TW508357B (es)
UA (2) UA46776C2 (es)
WO (2) WO1996040751A1 (es)
ZA (2) ZA964711B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2002088298A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
CA2683098C (en) * 2007-04-12 2014-03-18 Scinopharm Taiwan Ltd. Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103717595A (zh) 2011-05-27 2014-04-09 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP4400121A1 (en) 2021-09-03 2024-07-17 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
SG87056A1 (en) * 1991-08-09 2002-03-19 Teikoku Hormone Mfg Co Ltd Novel tetrapeptide derivative
DE69320339T2 (de) * 1992-05-20 1998-12-17 Basf Ag, 67063 Ludwigshafen Derivate des Dolastatin
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
SK282466B6 (sk) 2002-02-05
HUP9801817A2 (hu) 1998-11-30
BG102152A (en) 1998-09-30
HU228073B1 (hu) 2012-09-28
IL122216A0 (en) 1998-04-05
CA2219819A1 (en) 1996-12-19
KR100437985B1 (ko) 2004-09-18
BR9609424A (pt) 2000-03-28
BR9609423A (pt) 1999-06-29
HUP9801910A2 (hu) 1999-01-28
CN1187198A (zh) 1998-07-08
DE69623472T2 (de) 2003-08-21
SI0871656T1 (en) 2003-08-31
MX9709147A (es) 1998-03-31
HUP9801910A3 (en) 1999-06-28
IL122216A (en) 2002-02-10
SI0832104T1 (en) 2003-08-31
DE69623992T2 (de) 2003-05-22
HRP960257A2 (en) 1998-02-28
HUP9801817A3 (en) 1999-06-28
JPH11504653A (ja) 1999-04-27
MX9709146A (es) 1998-03-31
ATE224910T1 (de) 2002-10-15
CA2219818A1 (en) 1996-12-19
IL122215A (en) 2001-08-26
RO119783B1 (ro) 2005-03-30
KR100437986B1 (ko) 2004-09-18
JP3957751B2 (ja) 2007-08-15
JP4221062B2 (ja) 2009-02-12
AU6124296A (en) 1996-12-30
TR199701544T1 (xx) 1998-03-21
CZ376397A3 (cs) 1998-06-17
PL323726A1 (en) 1998-04-14
CZ293683B6 (cs) 2004-07-14
PL185763B1 (pl) 2003-07-31
CA2219818C (en) 2008-05-20
DE69623472D1 (de) 2002-10-10
NO975710L (no) 1998-02-02
CN1182154C (zh) 2004-12-29
UA46775C2 (uk) 2002-06-17
PL185762B1 (pl) 2003-07-31
SK165397A3 (en) 1998-10-07
UA46776C2 (uk) 2002-06-17
MY119042A (en) 2005-03-31
WO1996040751A1 (en) 1996-12-19
WO1996040752A1 (en) 1996-12-19
NO318384B1 (no) 2005-03-14
HU228071B1 (hu) 2012-09-28
EP0871656B1 (en) 2002-09-25
CA2219819C (en) 2008-05-20
EP0871656A1 (en) 1998-10-21
TR199701545T1 (xx) 1998-04-21
CZ293682B6 (cs) 2004-07-14
DK0832104T3 (da) 2003-01-06
ZA964711B (en) 1997-12-08
ATE223431T1 (de) 2002-09-15
AR003427A1 (es) 1998-08-05
CO4700527A1 (es) 1998-12-29
AU6124196A (en) 1996-12-30
AU725164B2 (en) 2000-10-05
CN1187199A (zh) 1998-07-08
NZ310444A (en) 1999-11-29
AU725170B2 (en) 2000-10-05
NO317670B1 (no) 2004-11-29
TW508357B (en) 2002-11-01
US5831002A (en) 1998-11-03
ES2186783T3 (es) 2003-05-16
AR003136A1 (es) 1998-07-08
KR19990022582A (ko) 1999-03-25
DE69623992D1 (de) 2002-10-31
NO975710D0 (no) 1997-12-05
PL323723A1 (en) 1998-04-14
KR19990022583A (ko) 1999-03-25
TW424096B (en) 2001-03-01
JPH11504652A (ja) 1999-04-27
HRP960277A2 (en) 1997-10-31
IL122215A0 (en) 1998-04-05
BG102125A (en) 1998-09-30
CZ376597A3 (cs) 1998-06-17
PT871656E (pt) 2002-12-31
RO118953B1 (ro) 2004-01-30
CN1182153C (zh) 2004-12-29
NZ310443A (en) 1999-10-28
PT832104E (pt) 2002-12-31
MY124487A (en) 2006-06-30
NO975711D0 (no) 1997-12-05
EP0832104A1 (en) 1998-04-01
DK0871656T3 (da) 2003-01-27
EP0832104B1 (en) 2002-09-04
CO4700526A1 (es) 1998-12-29
ZA964710B (en) 1997-12-08
NO975711L (no) 1998-01-30

Similar Documents

Publication Publication Date Title
ES2186783T3 (es) Derivados de la dolastatina, su preparacion y uso.
DK0723774T3 (da) Anvendelse af en antagonist for CGRP i en kosmetisk, farmaceutisk eller dermatologisk sammensætning og den opnåede sammensæ
ES2118955T3 (es) Derivados de dolastatina.
MX9203027A (es) Derivados heterociclicos de acilaminotiazoles y composicines farmaceuticas que los contienen.
IT8821134A0 (it) Frazioni oligomeriche procianidoliche, loro procedimentodi preparazione e composizioni farmaceutiche che le contengono.
ES2104673T3 (es) Hidroximetil(metilenciclopentil)purinas y pirimidinas.
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
IT9022032A0 (it) L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
BR9711586A (pt) Compostos e uso dos mesmo
ITMI951367A0 (it) Derivati della colchicina loro uso e formulazioni che li contengono
MX9204563A (es) Nuevos derivados de la (2-alquil-3-piridil)-metilpiperazina y composicion farmaceutica que los comprende.
MX9203505A (es) N-aril-n-(4-(1-alquilheterociclico)-piperidinil) amidas y composicines farmaceuticas y metodos que emplean dichos compuestos.
DE69006737D1 (de) Totalfeldabbildungssonde.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
FI971462A0 (fi) Bentsisoksatsolijohdannaisia ja niitä sisältäviä torjuntaainekoostumuksia
MX9203616A (es) Derivados de 4-amidino cromano y de 4-amidino[3,2-c] piridina y composiciones farmaceuticas que los contienen.
ITMI912466A0 (it) Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n-n-dimetiletanolammina in composizione dermatologiche
ES2105633T3 (es) Derivados de pirimidinona condensada a heterociclos nitrogenados con actividad antagonista de a ii.
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico
ES2158441T3 (es) Arilheterociclos con actividad herbicida.
DE69200210D1 (de) Klebrigkeitsprüfer.
ES2196802T3 (es) Lactatos de citronelilo y/o de dihidrocitronelilo, su preparacion y su utilizacion.
BA96113A (bs) Derivati 12,11113-epoksi-tilozina i postupci za njihovo dobivanje